对《美国使用每周一次司美格鲁肽与艾塞那肽缓释剂和度拉糖肽使患者达到糖化血红蛋白和体重减轻治疗目标的对照分析的相对成本》的更正
Correction to: A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA.
作者信息
Johansen Pierre, Hunt Barnaby, Iyer Neeraj N, Dang-Tan Tam, Pollock Richard F
机构信息
Novo Nordisk A/S, Søborg, Denmark.
Ossian Health Economics and Communications GmbH, Basel, Switzerland.
出版信息
Adv Ther. 2019 May;36(5):1200. doi: 10.1007/s12325-019-00945-2.
The article "A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA", written by Pierre Johansen, Barnaby Hunt, Neeraj N. Iyer, Tam Dang-Tan, Richard F. Pollock was originally published electronically on the publisher's internet portal (currently SpringerLink) on November 27, 2018 without Open Access.
皮埃尔·约翰森、巴纳比·亨特、内拉吉·N·伊耶、谭当坦、理查德·F·波洛克撰写的文章《司美格鲁肽每周一次与艾塞那肽缓释剂和度拉糖肽在美国使患者达到糖化血红蛋白和体重减轻治疗目标的对照分析相对成本》于2018年11月27日最初以电子方式在出版商的互联网门户网站（目前为SpringerLink）上发表，未开放获取。
Zotero 插件